Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
Climb Bio, Inc. reported that it has announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a clinical study of budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia. The study is designed to guide dose and regimen selection and to assess safety, platelet response and B-cell depletion in this patient group.
The company stated that it expects to release additional data from this trial by year-end 2026. It also included extensive cautionary language that these plans and expectations are forward-looking and subject to numerous risks, including clinical, regulatory, competitive and financing uncertainties related to budoprutug, CLYM116 and other product candidates.
Climb Bio, Inc. is registering the resale of up to 11,587,000 shares of its common stock for selling stockholders. This prospectus covers resale from time to time of 11,587,000 shares (9,481,000 outstanding shares and 2,106,000 shares issuable upon exercise of prefunded warrants) on behalf of the selling stockholders. The sales are resales by the selling stockholders; the company states it will not receive proceeds from resales, except that it will receive cash if the prefunded warrants are exercised for shares. The registration was filed to satisfy registration rights granted in connection with a private placement and includes a Beneficial Ownership Limitation of 33.0% that restricts exercise of the prefunded warrants. Shares outstanding were 57,263,023 as of May 14, 2026.
Climb Bio, Inc. reported a Form 4 showing a compensation-related stock option grant tied to RA Capital–associated entities. An option over 40,000 shares of Common Stock was awarded with an exercise price of $10.55 per share, expiring on June 4, 2036.
According to the footnotes, the option is held by Dr. Andrew Levin for the benefit of RA Capital Healthcare Fund and related Nexus funds and an account, and any net cash or stock from exercise will offset advisory fees owed to RA Capital Management, L.P. The reporting persons, including RA Capital entities and Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of any pecuniary interest. The option vests on the earlier of June 5, 2027 or the day immediately prior to the next annual stockholder meeting, subject to Dr. Levin’s continuous service.
Climb Bio, Inc. director Andrew David Levin was granted a stock option covering 40,000 shares of common stock at an exercise price of $10.55 per share. The option vests on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, contingent on continued service.
According to the disclosure, Levin holds this option for the benefit of RA Capital Healthcare Fund, related Nexus funds, and a separately managed account under an arrangement with RA Capital Management. Any net cash or stock from exercise must be turned over to the adviser to offset advisory fees, and Levin disclaims beneficial ownership of the option and underlying shares.
Climb Bio, Inc. director Kimberlee C. Drapkin received a grant of stock options covering 40,000 shares of Common Stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. Following this grant, she holds options on 40,000 shares directly. The options will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, subject to her continued service through that date.
Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. These options vest on the earlier of June 5, 2027 or immediately before the next annual meeting of stockholders, subject to his continued service. Following this grant, Williams holds 40,000 options directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Climb Bio, Inc. director Alexander Cumbo reported a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $10.55 per share, expire on June 4, 2036, and vest on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.
Climb Bio director Thomas Stephen Basil received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036.
The options will vest on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, as long as he continues to serve through that date.
Climb Bio, Inc. director Judith Dunn received a grant of stock options representing the right to buy 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. The 40,000 underlying shares will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, as long as she continues to serve through that date. Following this grant, she holds stock options for 40,000 shares directly.